Population Health Partners

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

Areteia Therapeutics is a biotechnology company focused on developing oral therapies for eosinophilic asthma to improve disease control. The company was spun out of Knopp and is advancing an oral drug designed to inhibit eosinophil maturation, aiming to reduce inflammation and alleviate symptoms of severe asthma. Phase 2 data from its program indicated the oral candidate lowers blood eosinophil counts, a marker associated with better lung function. By pursuing an oral, non-injectable treatment option, Areteia seeks to offer a convenient alternative to injectable therapies and broaden access for asthma patients. The company’s work centers on targeting eosinophil-related pathways to enhance asthma management and patient quality of life.

Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

Invivyd is a commercial-stage biopharmaceutical company dedicated to developing and commercializing antibody-based therapies aimed at protecting individuals from serious viral infectious diseases, particularly those with pandemic potential. The company focuses on innovative solutions that surpass the natural limits of immunity, starting with its lead product candidates for SARS-CoV-2. Notable among these candidates are ADG20, designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody optimized for enhanced potency and durability of protection. Invivyd's mission centers on delivering effective, long-lasting therapies to safeguard vulnerable populations from the severe repercussions of ongoing viral threats.